In the BioHarmony Drug Report Database

"Preview" Icon

Tafamidis

Vyndamax, Vyndaqel (tafamidis) is a small molecule pharmaceutical. Tafamidis was first approved as Vyndamax on 2011-11-16. It has been approved in Europe to treat amyloidosis. It is known to target transthyretin. Vyndaqel’s patents are valid until 2035-08-31 (FDA).

 

Trade Name

 

Vyndaqel
 

Common Name

 

tafamidis
 

ChEMBL ID

 

CHEMBL2103837
 

Indication

 

amyloidosis
 

Drug Class

 

Antimyloidotics

Image (chem structure or protein)

Tafamidis structure rendering